GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
GO:00616148 | Cervix | CC | pri-miRNA transcription by RNA polymerase II | 20/2311 | 55/18723 | 4.22e-06 | 1.09e-04 | 20 |
GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
GO:00092678 | Cervix | CC | cellular response to starvation | 39/2311 | 156/18723 | 1.04e-05 | 2.32e-04 | 39 |
GO:00425948 | Cervix | CC | response to starvation | 46/2311 | 197/18723 | 1.24e-05 | 2.59e-04 | 46 |
GO:19028938 | Cervix | CC | regulation of pri-miRNA transcription by RNA polymerase II | 19/2311 | 54/18723 | 1.27e-05 | 2.60e-04 | 19 |
GO:00316698 | Cervix | CC | cellular response to nutrient levels | 49/2311 | 215/18723 | 1.32e-05 | 2.68e-04 | 49 |
GO:00705859 | Cervix | CC | protein localization to mitochondrion | 33/2311 | 125/18723 | 1.46e-05 | 2.90e-04 | 33 |
GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EBF2 | SNV | Missense_Mutation | | c.1373C>T | p.Pro458Leu | p.P458L | Q9HAK2 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.593) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
EBF2 | SNV | Missense_Mutation | novel | c.202N>T | p.His68Tyr | p.H68Y | Q9HAK2 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
EBF2 | SNV | Missense_Mutation | | c.469N>A | p.Glu157Lys | p.E157K | Q9HAK2 | protein_coding | deleterious(0) | possibly_damaging(0.6) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EBF2 | SNV | Missense_Mutation | | c.1468N>G | p.Leu490Val | p.L490V | Q9HAK2 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.816) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
EBF2 | SNV | Missense_Mutation | | c.421N>A | p.Glu141Lys | p.E141K | Q9HAK2 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
EBF2 | SNV | Missense_Mutation | novel | c.1204N>G | p.Leu402Val | p.L402V | Q9HAK2 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.911) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
EBF2 | SNV | Missense_Mutation | novel | c.599C>G | p.Thr200Arg | p.T200R | Q9HAK2 | protein_coding | deleterious(0) | benign(0.142) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
EBF2 | SNV | Missense_Mutation | novel | c.725N>C | p.Arg242Thr | p.R242T | Q9HAK2 | protein_coding | deleterious(0) | possibly_damaging(0.491) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
EBF2 | SNV | Missense_Mutation | novel | c.8N>A | p.Gly3Glu | p.G3E | Q9HAK2 | protein_coding | deleterious_low_confidence(0.04) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EBF2 | SNV | Missense_Mutation | | c.1138C>G | p.Leu380Val | p.L380V | Q9HAK2 | protein_coding | tolerated(0.06) | benign(0.148) | TCGA-VS-A954-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |